AveXis Inc (AVXS) Rating Reiterated by Jefferies Group LLC

AveXis Inc (NASDAQ:AVXS)‘s stock had its “buy” rating reaffirmed by Jefferies Group LLC in a report issued on Wednesday. They presently have a $92.00 target price on the stock. Jefferies Group LLC’s target price indicates a potential upside of 19.48% from the company’s current price.

Other equities analysts have also issued research reports about the company. Chardan Capital set a $85.00 price target on AveXis and gave the company a “buy” rating in a research note on Sunday, December 25th. BMO Capital Markets restated an “outperform” rating and issued a $95.00 price target (up previously from $85.00) on shares of AveXis in a research note on Friday, March 17th. Goldman Sachs Group Inc lifted their price target on AveXis from $91.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, March 17th. Finally, Zacks Investment Research upgraded AveXis from a “sell” rating to a “hold” rating in a research note on Tuesday, February 14th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AveXis currently has a consensus rating of “Buy” and a consensus target price of $85.33.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Shares of AveXis (NASDAQ:AVXS) opened at 77.00 on Wednesday. The stock’s market cap is $2.14 billion. The company’s 50-day moving average price is $73.10 and its 200-day moving average price is $59.08. AveXis has a 52-week low of $21.42 and a 52-week high of $85.98.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, March 16th. The company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.15. During the same quarter in the previous year, the firm posted ($1.82) earnings per share. On average, equities research analysts forecast that AveXis will post ($4.10) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “AveXis Inc (AVXS) Rating Reiterated by Jefferies Group LLC” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/04/21/avexis-inc-avxs-rating-reiterated-by-jefferies-group-llc.html.

In related news, VP Sukumar Nagendran sold 1,781 shares of AveXis stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $76.13, for a total value of $135,587.53. Following the sale, the vice president now directly owns 1,781 shares in the company, valued at approximately $135,587.53. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

A number of large investors have recently bought and sold shares of AVXS. RTW Investments LLC boosted its stake in AveXis by 73.4% in the third quarter. RTW Investments LLC now owns 825,980 shares of the company’s stock valued at $34,039,000 after buying an additional 349,613 shares during the last quarter. RA Capital Management LLC boosted its stake in AveXis by 29.3% in the third quarter. RA Capital Management LLC now owns 1,732,274 shares of the company’s stock valued at $71,387,000 after buying an additional 392,892 shares during the last quarter. Great Point Partners LLC purchased a new stake in AveXis during the third quarter valued at about $15,703,000. Sphera Funds Management LTD. purchased a new stake in AveXis during the third quarter valued at about $4,121,000. Finally, Citadel Advisors LLC purchased a new stake in AveXis during the third quarter valued at about $13,565,000. Institutional investors own 68.31% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

5 Day Chart for NASDAQ:AVXS

Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply